Advertisement
Advertisement
Fortum

Fortum

ceftazidime

Manufacturer:

ACS Dobfar

Distributor:

Sandoz
Concise Prescribing Info
Contents
Ceftazidime
Indications/Uses
Single or multiple infections caused by susceptible organisms: Severe infections eg, septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed & ICU (eg, infected burns) patients; resp tract infections including lung infections in cystic fibrosis; ENT, UTI, skin & soft tissue, GI, biliary & abdominal, bone & joint infections; infections associated w/ haemo- & peritoneal dialysis & w/ continuous ambulatory peritoneal dialysis; prophylaxis to prostatic surgery (transurethral resection). Used as 1st choice drug before results of sensitivity tests are available; in combination w/ aminoglycoside or most other β-lactams; w/ antibiotic against anaerobes when presence of Bacteroides fragilis is suspected.
Dosage/Direction for Use
IV/IM Adult 1-6 g/day in 2 or 3 divided doses. UTI & less severe infection 500 mg or 1 g every 12 hr. Most infections 1 g every 8 hr or 2 g every 12 hr. Prophylaxis in prostatic surgery 1 g at induction of anaesth. Consider a 2nd dose at the time of catheter removal. Very severe infection particularly in immunocompromised patient including w/ neutropenia 2 g every 8 or 12 hr, or 3 g every 12 hr. Fibrocystic adult w/ pseudomonal lung infection 100-150 mg/kg/day in 3 divided doses. Infant & childn >2 mth 30-100 mg/kg/day in 2 or 3 divided doses. Immunocompromised or fibrocystic childn or childn w/ meningitis Up to 150 mg/kg/day in 3 divided doses. Max: 6 g/day. Neonate 0-2 mth 25-60 mg/kg daily in 2 divided doses. Elderly >80 yr Max daily dose: 3 g. Patient w/ renal impairment Initial loading dose: 1 g. Maintenance doses: CrCl >50 mL/min Normal dose, 50-31 mL/min 1 g 12 hrly, 30-16 mL/min 1 g 24 hrly, 15-6 mL/min 0.5 g 24 hrly, <5 mL/min 0.5 g 48 hrly. Severe infection Increase unit dose by 50% or increase dosing frequency. Serum level should not exceed 40 mg/mL. Haemodialysis Repeat maintenance dose following each haemodialysis period. Peritoneal dialysis Can be incorporated into dialysis fluid, usually 125-250 mg for 2 L of dialysis soln. Patient in renal failure on continuous arteriovenous haemodialysis or high-flux haemofiltration in intensive therapy units 1 g daily either as single dose or in divided doses. Patient in renal failure on low-flux haemofiltration Follow dosage recommended under renal impairment.
Contraindications
Hypersensitivity to ceftazidime pentahydrate or to cephalosporins.
Special Precautions
Patients w/ history of hypersensitivity reactions to ceftazidime, cephalosporins, penicillins, other β-lactams, or other drugs. Discontinue immediately if allergic reaction or prolonged/significant diarrhoea occurs; or patient experiences abdominal cramps. Prolonged use may result in overgrowth of non-susceptible organisms. Reports of pseudomembranous colitis. Some initially susceptible strains of Enterobacter spp & Serratia spp may develop resistance. Consider periodic susceptibility testing when clinically appropriate during therapy. Patients requiring Na restriction (contains Na 52 mg). Patients w/ renal impairment. Pregnancy & lactation.
Adverse Reactions
Eosinophilia, thrombocytosis; phlebitis or thrombophlebitis w/ IV administration; diarrhoea; transient elevations in ≥1 hepatic enzymes; maculopapular or urticarial rash; pain &/or inflammation after IM inj; +ve Coombs' test.
Drug Interactions
Concurrent treatment w/ high doses of cephalosporins & nephrotoxic drugs eg, aminoglycosides or potent diuretics (eg, furosemide) may adversely affect renal function. Possibility of antagonism w/ chloramphenicol. Lower oestrogen reabsorption & reduced efficacy of combined OCs. Slight interference may occur w/ Cu reduction methods (Benedict's, Fehling's, Clinitest).
MIMS Class
Cephalosporins
ATC Classification
J01DD02 - ceftazidime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Fortum powd for inj 1 g
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement